title: Bactobolin resistance is conferred by mutations in the L2 ribosomal protein.
abstract: Burkholderia thailandensis produces a family of polyketide-peptide molecules called bactobolins, some of which are potent antibiotics. We found that growth of B. thailandensis at 30°C versus that at 37°C resulted in increased production of bactobolins. We purified the three most abundant bactobolins and determined their activities against a battery of bacteria and mouse fibroblasts. Two of the three compounds showed strong activities against both bacteria and fibroblasts. The third analog was much less potent in both assays. These results suggested that the target of bactobolins might be conserved across bacteria and mammalian cells. To learn about the mechanism of bactobolin activity, we isolated four spontaneous bactobolin-resistant Bacillus subtilis mutants. We used genomic sequencing technology to show that each of the four resistant variants had mutations in rplB, which codes for the 50S ribosome-associated L2 protein. Ectopic expression of a mutant rplB gene in wild-type B. subtilis conferred bactobolin resistance. Finally, the L2 mutations did not confer resistance to other antibiotics known to interfere with ribosome function. Our data indicate that bactobolins target the L2 protein or a nearby site and that this is not the target of other antibiotics. We presume that the mammalian target of bactobolins involves the eukaryotic homolog of L2 (L8e).
  
  
  OBJECTIVE
  Currently available antibiotics target surprisingly few cellular functions, and there is a need to identify novel antibiotic targets. We have been interested in the Burkholderia thailandensis bactobolins, and we sought to learn about the target of bactobolin activity by mapping spontaneous resistance mutations in the bactobolin-sensitive Bacillus subtilis. Our results indicate that the bactobolin target is the 50S ribosome-associated L2 protein or a region of the ribosome affected by L2. Bactobolin-resistant mutants are not resistant to other known ribosome inhibitors. Our evidence indicates that bactobolins interact with a novel antibiotic target.
authors.affiliation: Department of Microbiology, School of Medicine, University of Washington, Seattle, Washington, USA.
authors.forename: Josephine R
authors.initials: JR
authors.lastname: Chandler
authors.forename: Thao T
authors.initials: TT
authors.lastname: Truong
authors.forename: Patricia M
authors.initials: PM
authors.lastname: Silva
authors.forename: Mohammad R
authors.initials: MR
authors.lastname: Seyedsayamdost
authors.forename: Gavin
authors.initials: G
authors.lastname: Carr
authors.forename: Matthew
authors.initials: M
authors.lastname: Radey
authors.forename: Michael A
authors.initials: MA
authors.lastname: Jacobs
authors.forename: Elizabeth H
authors.initials: EH
authors.lastname: Sims
authors.forename: Jon
authors.initials: J
authors.lastname: Clardy
authors.forename: E Peter
authors.initials: EP
authors.lastname: Greenberg
mesh_terms: D000818:Animals; D000900:Anti-Bacterial Agents / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology*; D001419:Bacteria / Q000187:drug effects; D001578:Benzopyrans / Q000302:isolation & purification / Q000378:metabolism / Q000494:pharmacology; D004252:DNA Mutational Analysis; D024881:Drug Resistance, Bacterial; D005347:Fibroblasts / Q000187:drug effects; D051379:Mice; D050505:Mutant Proteins / Q000235:genetics / Q000378:metabolism; D012269:Ribosomal Proteins / Q000235:genetics* / Q000378:metabolism*; D013696:Temperature
chemical_list: D000900:Anti-Bacterial Agents; D001578:Benzopyrans; D050505:Mutant Proteins; D012269:Ribosomal Proteins; C029466:ribosomal protein L2; C025268:bactobolin